Levitronix as a Short-term Salvage Treatment for Primary Graft Failure After Heart Transplantation
Received 30 July 2005; received in revised form 24 November 2005; accepted 27 November 2005. published online 27 March 2006.
Background
Primary graft failure after heart transplantation is a well-recognized catastrophic complication with a high mortality rate. It is becoming more frequent due to the increasing use of marginal donors. In these difficult cases a ventricular assist device (VAD) as a bridge to recovery or as a bridge to re-transplantation can be used. The recently introduced Levitronix Centrimag centrifugal pump might be an ideal device for this purpose.
Methods
In this study we describe 2 patients with primary graft failure who received a Levitronix in the last 2 years, immediately after failure to wean from cardiopulmonary bypass. Biventricular support was necessary in both patients.
Results
One patient was successfully re-transplanted after 2 days of support, and subsequently discharged. After 16 months she has good ventricular function with no symptoms of cardiac failure. The second patient showed signs of ventricular recovery after a few days and was weaned from the device after 7 days, with good graft function. No device-related complications were recorded. After 14 days he was discharged from the intensive care unit (ICU), and a post-operative echocardiogram showed normal dimensions, good ejection fraction and no valvular regurgitation. He was discharged home 26 days after the transplant.
Conclusions
In our experience, the Levitronix Centrimag seems to be safe and effective in the treatment of primary graft failure, achieving effective circulatory support and ventricular off-loading. We propose its use in isolated or biventricular graft failure either as bridge to re-transplant or as a bridge to recovery.
Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, UK
Reprint requests: Emma J. Birks, PhD, Transplant Medicine, Harefield Hospital, Hill End Road, Harefield, Middlesex UB9 6JH, UK. Tel: 0044-18-95-82-6511. Fax: 0044-18-95-82-6512
ABSTRACT